Europe: Food, Drugs, Healthcare, Life Sciences

L'Amérique latine fait face à un défi majeur dans la transformation de ses innovations brevetées en valeur économique tangible. Cette analyse examine les obstacles structurels et stratégiques qui empêchent la région de capitaliser pleinement sur son potentiel d'innovation et de propriété intellectuelle.

Artificial intelligence is transforming how pharmaceutical companies identify new therapeutic uses for existing drugs, but this acceleration creates complex intellectual property challenges. As computational methods rapidly generate repurposing candidates, innovators must navigate the tension between filing early to secure priority and waiting for sufficient validation data, while ensuring their second medical use patents provide meaningful commercial protection in an increasingly competitive landscape.

Bär & Karrer, a Swiss law firm, provides comprehensive legal and business solutions. Contact their Zurich office for expert assistance with legal advice, business inquiries, and professional services tailored to your needs.

Healthcare services around the world are coming under increasing pressure as lengthening life expectancies and aging populations drive patient demand ever higher.

Hungary has become an increasingly popular destination for retirees looking to enjoy a high quality of life in the heart of Europe. With its rich culture, safe environment, and relatively low cost of living compared to Western Europe, the country offers an appealing combination of comfort and affordability.

In a new landmark ruling, the Swiss Federal Supreme Court has clarified that non-accused third parties may also invoke protection of legal privilege, privacy and other legally protected secrets, such as the medical secret, in the context of unsealing proceedings.

Recent U.S. case law is reshaping the risks around skinny labelling strategies for generics. What was once seen as a safe regulatory pathway now raises new concerns about infringement

Turkey's Product Safety and Technical Regulations Law No. 7223 establishes a comprehensive liability framework for all economic operators in the dietary supplement sector, from importers and distributors to authorized representatives.

The MHRA’s proposed rare disease therapies regulatory framework (“the Proposed Framework”) represents an ambitious attempt to redesign medicines regulation around the realities of rare disease development.